Secondary-school pupils in England appear to be rejecting cigarettes in greater numbers than ever before. The most recent survey in a series that began in the 1980s indicates just 16% of the pupils have ever smoked tobacco, down from 19% in 2016 and 49% in 1996. However, a quarter of the 13,000 pupils surveyed, from… Read More: More schoolchildren ‘rejecting cigarettes’ »
Do you want to lose weight? If you do you are not alone. An estimated 160 million Americans, including males and females , are either obese or overweight . America has a severe obesity epidemic that has serious long term health implications. The cause of the obesity epidemic is the American lifestyle. This means… Read More: FIGHTING THE SUGAR MONSTER A never ending battle »
FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis Print this page SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.1 “The approval… Read More: FDA Approves Inrebic (fedratinib) for the Treatment of Patients With… »
FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis Print this page NORTH CHICAGO, Ill., Aug. 16, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral… Read More: FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the… »